Globeflex Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Globeflex Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,600	Closed	-$454K	–	473
2016 Q3	$454K	Hold	8,600	–	–	0.11%	258
2016 Q2	$360K	Hold	8,600	–	–	0.1%	277
2016 Q1	$349K	Hold	8,600	–	–	0.09%	272
2015 Q4	$558K	Hold	8,600	–	–	0.15%	215
2015 Q3	$607K	Sell	8,600 -1,400	-14%	-$137K	0.13%	262
2015 Q2	$1.11M	Buy	+10,000	New	+$1.08M	0.2%	191

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Globeflex Capital's AGIO Position: Q4 2016 in Review

Globeflex Capital sold out of Agios Pharmaceuticals (AGIO) in Q4 2016, closing a stake of 8,600 shares — an estimated $454K sold.

Globeflex Capital first reported a position in AGIO in Q2 2015 and held it in 6 quarters. The position peaked at $1.11M in Q2 2015. 161 funds tracked by Wall St. Rank hold AGIO as of Q4 2016.

Globeflex Capital reported no remaining Agios Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Globeflex Capital sold 8,600 Agios Pharmaceuticals shares in Q4 2016, an estimated $454K.
Globeflex Capital first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Globeflex Capital's Agios Pharmaceuticals position peaked at $1.11M in Q2 2015.
161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2016.

Based on Globeflex Capital's 13F filing for Q4 2016, filed 13 Feb 2017.